Everest Consolidator Acquisition Co. (NYSE:MNTN – Get Rating)'s stock price traded up 0.1% during mid-day trading on Tuesday . The company traded as high as $10.42 and last traded at $10.41. 157,229 shares were traded during trading, an increase of 139% from the average session volume of 65,879 shares. The stock had previously closed at $10.40.
Everest Consolidator Acquisition Stock Up 0.1 %
The firm has a 50 day simple moving average of $10.31 and a two-hundred day simple moving average of $10.17.
Get Everest Consolidator Acquisition alerts:Hedge Funds Weigh In On Everest Consolidator Acquisition
A number of institutional investors have recently made changes to their positions in the stock. Woodline Partners LP purchased a new stake in shares of Everest Consolidator Acquisition in the second quarter valued at $2,994,000. Landscape Capital Management L.L.C. purchased a new stake in Everest Consolidator Acquisition during the fourth quarter valued at about $1,082,000. Marshall Wace LLP purchased a new stake in Everest Consolidator Acquisition during the third quarter valued at about $198,000. Finally, Elequin Securities LLC purchased a new stake in Everest Consolidator Acquisition during the fourth quarter valued at about $57,000. 67.01% of the stock is owned by institutional investors and hedge funds.
Everest Consolidator Acquisition Company Profile
(Get Rating)
Everest Consolidator Acquisition Corporation does not have significant operations. The company intends to acquire assets and businesses or entities through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination. It focuses on identifying businesses in the wealth management industry.
Recommended Stories
- Get a free copy of the StockNews.com research report on Everest Consolidator Acquisition (MNTN)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets "Powelled": S&P 500 Confirms Resistance
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Rivian Plummets, But Is This 2023's Greatest Buying Opportunity?
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Everest Consolidator Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everest Consolidator Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.